New research announced at the International Liver Congress 2014 today provides new hope for the notoriously difficult-to-treat population of liver transplant patients with recurring hepatitis C (HCV).
Apr 11, 2014
0
0
(HealthDay)—For patients with hepatitis C virus (HCV) treated with pegylated interferon-alpha and ribavirin (P/R), drinking patterns and the amount of alcohol consumed before treatment do not impact treatment success, according ...
Oct 11, 2012
0
0
Abbott Laboratories said Monday that its experimental hepatitis C drug regimen cured 99 percent of patients in a midstage study with the most common and hardest-to-treat type of the disease.
Oct 15, 2012
0
0
(HealthDay)—Sofosbuvir seems to be a promising treatment option for patients with chronic hepatitis C virus (HCV) infection, according to two studies published online April 23 in the New England Journal of Medicine to coincide ...
Apr 23, 2013
0
0
Results presented today at The International Liver Congress 2015 show that the use of the fixed-dose combination of ledipasvir/sofosbuvir (LDV/SOF) in combination with ribavirin (RBV) was well tolerated and demonstrated high ...
Apr 23, 2015
0
6
(HealthDay)—For untreated patients with hepatitis C virus (HCV), treatment with an oral nucleotide inhibitor of HCV polymerase, sofosbuvir, plus ribavirin seems effective for genotypes 1, 2, and 3; and the HCV NS3 protease ...
Jan 3, 2013
0
0
Results presented today at The International Liver Congress 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ...
Apr 25, 2015
0
4
Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver Congress 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon ...
Apr 12, 2014
0
0
Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.
Jan 15, 2014
0
0
National Institutes of Health (NIH) scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown ...
Apr 18, 2013
0
0
